GENFIT S.A Gross Profit 2019-2021 | GNFT

GENFIT S.A gross profit from 2019 to 2021. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
GENFIT S.A Annual Gross Profit
(Millions of US $)
2021 $101
2020 $9
2019 $46
2018 $9
GENFIT S.A Quarterly Gross Profit
(Millions of US $)
2021-12-31
2021-06-30
2020-12-31
2020-06-30
2019-12-31
2019-06-30
2018-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.170B $0.101B
Genfit SA is a biopharmaceutical company. It focuses on the discovery and development of therapeutic and diagnostic solutions in metabolic and liver related diseases. The company's lead products include Elafibranor, Nitazoxanide and TGFTX1 which are in clinical stage. Genfit SA is based in Loos, France.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $165.194B 10.05
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.361B 16.35
Biohaven Pharmaceutical Holding (BHVN) United States $10.098B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.208B 0.00
Emergent Biosolutions (EBS) United States $1.617B 6.92
Arcus Biosciences (RCUS) United States $1.305B 33.09
Myovant Sciences (MYOV) United Kingdom $0.956B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.500B 0.00
Zymeworks (ZYME) Canada $0.368B 0.00
Gelesis Holdings (GLS) United States $0.349B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.108B 22.10
SQZ Biotechnologies (SQZ) United States $0.097B 0.00